Down-regulation of beta catenin inhibits the growth of esophageal carcinoma cells

Nirmal K. Veeramachaneni, Hirotoshi Kubokura, Li Lin, James A. Pippin, G. Alexander Patterson, Jeffrey A. Drebin, Richard J Battafarano, W. Roy Smythe, David A. Jones, Raphael Bueno, Dao M. Nguyen

Research output: Contribution to journalArticle

Abstract

Introduction: Esophageal cancer remains a highly lethal malignancy, with therapeutic options of limited efficacy in the majority of patients. Understanding the molecular events involved in the pathogenesis of esophageal cancer offers insight into potential targets for treatment. Beta catenin and Wnt signaling abnormalities are involved in the development of both adenocarcinoma and squamous carcinoma of the esophagus. We hypothesized that down-regulation of beta catenin would inhibit the growth of human esophageal cancer. Methods: A human esophageal squamous cell carcinoma cell line (TE10) was treated with phosphorothioate antisense oligonucleotides to beta catenin. The cells were subsequently assayed for beta catenin mRNA and protein by real-time polymerase chain reaction and Western blot. Beta catenin transcriptional activity was determined by TOPFlash assay. Cell viability and growth was assessed by methyl-thiazol-diphenyl-tetrazolium assay and trypan blue exclusion. A colorimetric assay was employed to assess caspase 3 activity, and flow cytometry was done to determine percentage of cells in a given phase of the cell cycle. Results: Following antisense treatment, beta catenin mRNA and protein concentration were decreased. There was corresponding decrease in beta catenin-transcription factor-dependent transcription. Treatment with beta catenin antisense resulted in significantly decreased cell viability and proliferation. The mechanism appears to be increased induction of apoptosis. Conclusions: These data suggest a potential role for the targeting of beta catenin in the treatment of esophageal cancer.

Original languageEnglish (US)
Pages (from-to)92-98
Number of pages7
JournalJournal of Thoracic and Cardiovascular Surgery
Volume127
Issue number1
DOIs
StatePublished - Jan 2004
Externally publishedYes

Fingerprint

beta Catenin
Down-Regulation
Carcinoma
Growth
Esophageal Neoplasms
Catenins
Cell Survival
Phosphorothioate Oligonucleotides
Therapeutics
Messenger RNA
Trypan Blue
Antisense Oligonucleotides
Caspase 3
Esophagus
Real-Time Polymerase Chain Reaction
Squamous Cell Carcinoma
Cell Cycle
Flow Cytometry
Adenocarcinoma
Transcription Factors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Veeramachaneni, N. K., Kubokura, H., Lin, L., Pippin, J. A., Patterson, G. A., Drebin, J. A., ... Nguyen, D. M. (2004). Down-regulation of beta catenin inhibits the growth of esophageal carcinoma cells. Journal of Thoracic and Cardiovascular Surgery, 127(1), 92-98. https://doi.org/10.1016/j.jtcvs.2003.06.008

Down-regulation of beta catenin inhibits the growth of esophageal carcinoma cells. / Veeramachaneni, Nirmal K.; Kubokura, Hirotoshi; Lin, Li; Pippin, James A.; Patterson, G. Alexander; Drebin, Jeffrey A.; Battafarano, Richard J; Smythe, W. Roy; Jones, David A.; Bueno, Raphael; Nguyen, Dao M.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 127, No. 1, 01.2004, p. 92-98.

Research output: Contribution to journalArticle

Veeramachaneni, NK, Kubokura, H, Lin, L, Pippin, JA, Patterson, GA, Drebin, JA, Battafarano, RJ, Smythe, WR, Jones, DA, Bueno, R & Nguyen, DM 2004, 'Down-regulation of beta catenin inhibits the growth of esophageal carcinoma cells', Journal of Thoracic and Cardiovascular Surgery, vol. 127, no. 1, pp. 92-98. https://doi.org/10.1016/j.jtcvs.2003.06.008
Veeramachaneni, Nirmal K. ; Kubokura, Hirotoshi ; Lin, Li ; Pippin, James A. ; Patterson, G. Alexander ; Drebin, Jeffrey A. ; Battafarano, Richard J ; Smythe, W. Roy ; Jones, David A. ; Bueno, Raphael ; Nguyen, Dao M. / Down-regulation of beta catenin inhibits the growth of esophageal carcinoma cells. In: Journal of Thoracic and Cardiovascular Surgery. 2004 ; Vol. 127, No. 1. pp. 92-98.
@article{bc129152f7cc4ddda0f67fd94b76aa8c,
title = "Down-regulation of beta catenin inhibits the growth of esophageal carcinoma cells",
abstract = "Introduction: Esophageal cancer remains a highly lethal malignancy, with therapeutic options of limited efficacy in the majority of patients. Understanding the molecular events involved in the pathogenesis of esophageal cancer offers insight into potential targets for treatment. Beta catenin and Wnt signaling abnormalities are involved in the development of both adenocarcinoma and squamous carcinoma of the esophagus. We hypothesized that down-regulation of beta catenin would inhibit the growth of human esophageal cancer. Methods: A human esophageal squamous cell carcinoma cell line (TE10) was treated with phosphorothioate antisense oligonucleotides to beta catenin. The cells were subsequently assayed for beta catenin mRNA and protein by real-time polymerase chain reaction and Western blot. Beta catenin transcriptional activity was determined by TOPFlash assay. Cell viability and growth was assessed by methyl-thiazol-diphenyl-tetrazolium assay and trypan blue exclusion. A colorimetric assay was employed to assess caspase 3 activity, and flow cytometry was done to determine percentage of cells in a given phase of the cell cycle. Results: Following antisense treatment, beta catenin mRNA and protein concentration were decreased. There was corresponding decrease in beta catenin-transcription factor-dependent transcription. Treatment with beta catenin antisense resulted in significantly decreased cell viability and proliferation. The mechanism appears to be increased induction of apoptosis. Conclusions: These data suggest a potential role for the targeting of beta catenin in the treatment of esophageal cancer.",
author = "Veeramachaneni, {Nirmal K.} and Hirotoshi Kubokura and Li Lin and Pippin, {James A.} and Patterson, {G. Alexander} and Drebin, {Jeffrey A.} and Battafarano, {Richard J} and Smythe, {W. Roy} and Jones, {David A.} and Raphael Bueno and Nguyen, {Dao M.}",
year = "2004",
month = "1",
doi = "10.1016/j.jtcvs.2003.06.008",
language = "English (US)",
volume = "127",
pages = "92--98",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Down-regulation of beta catenin inhibits the growth of esophageal carcinoma cells

AU - Veeramachaneni, Nirmal K.

AU - Kubokura, Hirotoshi

AU - Lin, Li

AU - Pippin, James A.

AU - Patterson, G. Alexander

AU - Drebin, Jeffrey A.

AU - Battafarano, Richard J

AU - Smythe, W. Roy

AU - Jones, David A.

AU - Bueno, Raphael

AU - Nguyen, Dao M.

PY - 2004/1

Y1 - 2004/1

N2 - Introduction: Esophageal cancer remains a highly lethal malignancy, with therapeutic options of limited efficacy in the majority of patients. Understanding the molecular events involved in the pathogenesis of esophageal cancer offers insight into potential targets for treatment. Beta catenin and Wnt signaling abnormalities are involved in the development of both adenocarcinoma and squamous carcinoma of the esophagus. We hypothesized that down-regulation of beta catenin would inhibit the growth of human esophageal cancer. Methods: A human esophageal squamous cell carcinoma cell line (TE10) was treated with phosphorothioate antisense oligonucleotides to beta catenin. The cells were subsequently assayed for beta catenin mRNA and protein by real-time polymerase chain reaction and Western blot. Beta catenin transcriptional activity was determined by TOPFlash assay. Cell viability and growth was assessed by methyl-thiazol-diphenyl-tetrazolium assay and trypan blue exclusion. A colorimetric assay was employed to assess caspase 3 activity, and flow cytometry was done to determine percentage of cells in a given phase of the cell cycle. Results: Following antisense treatment, beta catenin mRNA and protein concentration were decreased. There was corresponding decrease in beta catenin-transcription factor-dependent transcription. Treatment with beta catenin antisense resulted in significantly decreased cell viability and proliferation. The mechanism appears to be increased induction of apoptosis. Conclusions: These data suggest a potential role for the targeting of beta catenin in the treatment of esophageal cancer.

AB - Introduction: Esophageal cancer remains a highly lethal malignancy, with therapeutic options of limited efficacy in the majority of patients. Understanding the molecular events involved in the pathogenesis of esophageal cancer offers insight into potential targets for treatment. Beta catenin and Wnt signaling abnormalities are involved in the development of both adenocarcinoma and squamous carcinoma of the esophagus. We hypothesized that down-regulation of beta catenin would inhibit the growth of human esophageal cancer. Methods: A human esophageal squamous cell carcinoma cell line (TE10) was treated with phosphorothioate antisense oligonucleotides to beta catenin. The cells were subsequently assayed for beta catenin mRNA and protein by real-time polymerase chain reaction and Western blot. Beta catenin transcriptional activity was determined by TOPFlash assay. Cell viability and growth was assessed by methyl-thiazol-diphenyl-tetrazolium assay and trypan blue exclusion. A colorimetric assay was employed to assess caspase 3 activity, and flow cytometry was done to determine percentage of cells in a given phase of the cell cycle. Results: Following antisense treatment, beta catenin mRNA and protein concentration were decreased. There was corresponding decrease in beta catenin-transcription factor-dependent transcription. Treatment with beta catenin antisense resulted in significantly decreased cell viability and proliferation. The mechanism appears to be increased induction of apoptosis. Conclusions: These data suggest a potential role for the targeting of beta catenin in the treatment of esophageal cancer.

UR - http://www.scopus.com/inward/record.url?scp=10744222577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744222577&partnerID=8YFLogxK

U2 - 10.1016/j.jtcvs.2003.06.008

DO - 10.1016/j.jtcvs.2003.06.008

M3 - Article

C2 - 14752418

AN - SCOPUS:10744222577

VL - 127

SP - 92

EP - 98

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 1

ER -